Enter measurements in mm. Non-nodal: longest diameter. Lymph nodes: short axis.
2 Additional Criteria
About RECIST 1.1
Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 is the standard method for evaluating tumor response to treatment. Published in 2009, it provides reproducible criteria for classifying response in clinical trials and practice.
Response Categories
Response
Criteria
CR (Complete Response)
Disappearance of all target lesions. All lymph nodes <10mm short axis.
PR (Partial Response)
≥30% decrease in sum of diameters from baseline
SD (Stable Disease)
Neither sufficient decrease for PR nor increase for PD
PD (Progressive Disease)
≥20% increase from nadir AND ≥5mm absolute increase. Or new lesion.
Target Lesion Selection
Maximum 5 lesions total, 2 per organ
Select largest, most reproducibly measurable lesions
Non-nodal: ≥10mm longest diameter (CT slice ≤5mm)
Lymph nodes: ≥15mm short axis (pathological)
Measurement Rules
Non-nodal lesions: Measure longest diameter
Lymph nodes: Measure short axis (even when used as target)
Too small to measure: Use 5mm default
Disappeared: Record as 0mm
Lesions merge: Measure combined longest axis
Lesions split: Sum individual measurements
The 5mm Rule
To prevent false PD from measurement variability, progression requires both:
≥20% increase from nadir
≥5mm absolute increase
If only percentage threshold met but absolute change <5mm, classify as SD.
Nadir: Lowest sum during treatment (for PD calculation)
Nadir may equal baseline if no decrease occurred
References
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1 - Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132-137. doi:10.1016/j.ejca.2016.03.081
Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2010;5(12):2044-2048. doi:10.1097/JTO.0b013e3181f60709